51,290 Shares in Glaukos Corporation $GKOS Purchased by EFG International AG

EFG International AG bought a new stake in Glaukos Corporation (NYSE:GKOS) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 51,290 shares of the medical instruments supplier’s stock, valued at approximately $7,161,000. EFG International AG owned approximately 0.09% of Glaukos as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. AQR Capital Management LLC boosted its holdings in shares of Glaukos by 2.6% in the first quarter. AQR Capital Management LLC now owns 7,788 shares of the medical instruments supplier’s stock valued at $766,000 after acquiring an additional 198 shares in the last quarter. Jones Financial Companies Lllp raised its holdings in Glaukos by 1,405.9% during the first quarter. Jones Financial Companies Lllp now owns 2,560 shares of the medical instruments supplier’s stock worth $252,000 after purchasing an additional 2,390 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Glaukos by 41.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 229,994 shares of the medical instruments supplier’s stock worth $22,636,000 after purchasing an additional 67,668 shares in the last quarter. M&T Bank Corp acquired a new stake in Glaukos in the second quarter worth approximately $203,000. Finally, Gamco Investors INC. ET AL lifted its position in Glaukos by 10.7% in the second quarter. Gamco Investors INC. ET AL now owns 8,001 shares of the medical instruments supplier’s stock worth $826,000 after purchasing an additional 773 shares during the period. Institutional investors and hedge funds own 99.04% of the company’s stock.

Insider Buying and Selling

In related news, Director Leana Wen sold 525 shares of Glaukos stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $167.63, for a total value of $88,005.75. Following the transaction, the director owned 21,092 shares of the company’s stock, valued at approximately $3,535,651.96. This trade represents a 2.43% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Alex R. Thurman sold 20,000 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $180.13, for a total value of $3,602,600.00. Following the sale, the chief financial officer owned 43,906 shares in the company, valued at approximately $7,908,787.78. The trade was a 31.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 113,025 shares of company stock worth $19,600,006. Company insiders own 5.90% of the company’s stock.

Glaukos Stock Performance

GKOS opened at $181.48 on Wednesday. The firm has a market cap of $10.70 billion, a PE ratio of -55.84 and a beta of 0.78. The company has a quick ratio of 4.46, a current ratio of 5.04 and a debt-to-equity ratio of 0.10. The business has a fifty day simple moving average of $159.57 and a 200-day simple moving average of $132.67. Glaukos Corporation has a fifty-two week low of $73.16 and a fifty-two week high of $191.62.

Glaukos (NYSE:GKOS) last issued its earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.07. The business had revenue of $185.61 million for the quarter, compared to analysts’ expectations of $150.93 million. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%.The company’s quarterly revenue was up 49.6% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.24) EPS. As a group, equities analysts predict that Glaukos Corporation will post -0.32 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Stifel Nicolaus lifted their price target on Glaukos from $175.00 to $190.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Needham & Company LLC raised their target price on Glaukos from $150.00 to $201.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. HC Wainwright lifted their target price on Glaukos from $168.00 to $195.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Piper Sandler reissued an “overweight” rating and issued a $195.00 price target (up from $165.00) on shares of Glaukos in a report on Thursday, July 30th. Finally, JPMorgan Chase & Co. upped their price target on shares of Glaukos from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Twelve research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $178.08.

Glaukos Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.